Movement Alert｜Twist Bioscience Corp Rises 5.43% in Regular Trading, Revenue Guidance Significantly Exceeds Expectations Driving Rebound

Market Focus08-07 22:05

On August 7, Twist Bioscience Corp rose 5.43% in regular trading, trading at $114.78/share, with turnover of $18.7 million. The stock continued its rebound momentum following the release of strong fiscal Q3 results and forward guidance.

The company reported fiscal Q3 revenue of $118.4 million, representing 23.2% year-over-year growth and beating the analyst consensus estimate of $114.5 million. More critically, the company raised its full-year revenue guidance to $456-$457 million and projected Q4 revenue of $123-$124 million, significantly above the FactSet consensus of $117.4 million. While EPS of -$0.56 missed the -$0.50 estimate, the robust top-line growth and upbeat forward outlook continued to bolster investor confidence in the company's business expansion trajectory.

Since the earnings release on August 3, the stock has experienced volatile trading with sharp multi-directional swings, initially dropping over 9% before recovering more than 6%. Evercore ISI had previously downgraded the stock to In Line in July while raising the price target to $102, reflecting ongoing debate between high valuation and profitability concerns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171077658?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171077658","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Corp Rises 5.43% in Regular Trading, Revenue Guidance Significantly Exceeds Expectations Driving Rebound","media":"Market Focus","content":"<p><p>On August 7, Twist Bioscience Corp rose 5.43% in regular trading, trading at $114.78/share, with turnover of $18.7 million. The stock continued its rebound momentum following the release of strong fiscal Q3 results and forward guidance.</p><p>The company reported fiscal Q3 revenue of $118.4 million, representing 23.2% year-over-year growth and beating the analyst consensus estimate of $114.5 million. More critically, the company raised its full-year revenue guidance to $456-$457 million and projected Q4 revenue of $123-$124 million, significantly above the FactSet consensus of $117.4 million. While EPS of -$0.56 missed the -$0.50 estimate, the robust top-line growth and upbeat forward outlook continued to bolster investor confidence in the company's business expansion trajectory.</p><p>Since the earnings release on August 3, the stock has experienced volatile trading with sharp multi-directional swings, initially dropping over 9% before recovering more than 6%. Evercore ISI had previously downgraded the stock to In Line in July while raising the price target to $102, reflecting ongoing debate between high valuation and profitability concerns.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Corp Rises 5.43% in Regular Trading, Revenue Guidance Significantly Exceeds Expectations Driving Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Corp Rises 5.43% in Regular Trading, Revenue Guidance Significantly Exceeds Expectations Driving Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Twist Bioscience Corp rose 5.43% in regular trading, trading at $114.78/share, with turnover of $18.7 million. The stock continued its rebound momentum following the release of strong fiscal Q3 results and forward guidance.</p><p>The company reported fiscal Q3 revenue of $118.4 million, representing 23.2% year-over-year growth and beating the analyst consensus estimate of $114.5 million. More critically, the company raised its full-year revenue guidance to $456-$457 million and projected Q4 revenue of $123-$124 million, significantly above the FactSet consensus of $117.4 million. While EPS of -$0.56 missed the -$0.50 estimate, the robust top-line growth and upbeat forward outlook continued to bolster investor confidence in the company's business expansion trajectory.</p><p>Since the earnings release on August 3, the stock has experienced volatile trading with sharp multi-directional swings, initially dropping over 9% before recovering more than 6%. Evercore ISI had previously downgraded the stock to In Line in July while raising the price target to $102, reflecting ongoing debate between high valuation and profitability concerns.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1171077658","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171077658","pubTimestamp":1786111545,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Twist Bioscience Corp rose 5.43% in regular trading, trading at $114.78/share, with turnover of $18.7 million. The stock continued its rebound momentum following the release of strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"走势提醒|Twist Bioscience Corp常规交易上涨5.43%，收入指引大幅超预期推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On August 7, Twist Bioscience Corp rose 5.43% in regular trading, trading at $114.78/share, with turnover of $18.7 million. The stock continued its rebound momentum following the release of strong fiscal Q3 results and forward guidance.The company reported fiscal Q3 revenue of $118.4 million, representing 23.2% year-over-year growth and beating the analyst consensus estimate of $114.5 million. More critically, the company raised its full-year revenue guidance to $456-$457 million and projected Q4 revenue of $123-$124 million, significantly above the FactSet consensus of $117.4 million. While EPS of -$0.56 missed the -$0.50 estimate, the robust top-line growth and upbeat forward outlook continued to bolster investor confidence in the company's business expansion trajectory.Since the earnings release on August 3, the stock has experienced volatile trading with sharp multi-directional swings, initially dropping over 9% before recovering more than 6%. Evercore ISI had previously downgraded the stock to In Line in July while raising the price target to $102, reflecting ongoing debate between high valuation and profitability concerns.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171077658","isCrawlerRequest":true}